Brought to you by 
Shire buys Transkaryotic Therapies for $1.57bn
09 May 2005
Executive Summary
Shire Pharmaceuticals Group PLC has signed a definitive agreement to purchase Transkaryotic Therapies (TKT; protein replacement therapies for rare genetic diseases) for $1.57bn in cash. Shire will buy TKT's fully diluted shares for $37 each, a 31% premium to the average market price.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire buys Transkaryotic Therapies for $1.57bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice